Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Dips Its Toes in Disruptive IVD Tech

Executive Summary

The number of Chinese IVD companies exhibiting at the 2015 American Association for Clinical Chemistry Annual Meeting (AACC) & Clinical Lab Expo (CLE) was slightly down from last year, but the breadth of diagnostic products and innovations from China appears to be on the up. Hrishi Poola and Jon Chen discuss the moves China is making to become a generator of disruptive technologies and reports on the new products and the players emerging from this market

You may also be interested in...



NAD SWIFT Cases Get Swifter, More Frequent As Stakeholders Embrace Fast-Track Process

The BBB National Program Inc. expects to double the number of National Advertising Division SWIFT reviews completed in 2023 compared with last year as stakeholders grow more comfortable with the process. At its annual conference in Philadelphia 19-20 September, NAD said it is speeding up the time it takes to complete both SWIFT and standard track reviews.

Pierre Fabre Continues Oncology R&D Push

The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.

Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success

The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel